Alkermes price target raised to $55 from $50 at Truist

Truist raised the firm’s price target on Alkermes (ALKS) to $55 from $50 and keeps a Buy rating on the shares. Positive Vibrance-2 results materially de-risk the alixorexton program, supporting a higher probability of success and stronger estimates, the analyst tells investors in a research note. Cross-trial comparisons show alixorexton outperforming oveporexton in NT2, and the added split-dosing regimen in Phase 3 could further enhance efficacy, with Takeda (TAK) management viewing the program as credible competitive pressure.